Navigation Links
Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
Date:7/25/2008

etabolic biomarkers as well as evaluations of mood and cognition were also found to be stable in subjects receiving all levels of the drug or placebo during the trial. These positive Study MSI-1436C-103 results are expected to enable further study to fully validate proof-of-concept of MSI-1436 in an ascending multiple-dose clinical trial planned to begin later this year.

Data were also presented from preclinical studies which demonstrated that systemically administered MSI-1436 crossed the blood-brain barrier and functionally inhibited PTP1B in the hypothalamus. In this study, rats were administered a single dose of MSI-1436 one day prior to receiving insulin; 30 minutes post-insulin, hypothalami were harvested to determine the level of phosphorylated-insulin receptor beta (IR-beta), a target of PTP1B. Previous studies had shown that MSI-1436 is a reversible, noncompetitive inhibitor of PTP1B with the ability to cross the blood brain barrier. In the hypothalamus, MSI-1436 enhanced the insulin-induced phosphorylative state of the insulin receptor, which confirms the functionality of MSI-1436 in this key regulatory center of the brain. The combination of central and peripheral inhibition makes MSI-1436 a promising therapeutic candidate for both obesity and type 2 diabetes.

"The data reported today support continuing confidence in our ability to administer trodusquemine to a wide range of obese and type 2 diabetic patients," stated Jack Armstrong, President and Chief Executive Officer of Genaera. "MSI-1436 is the only reversible, noncompetitive inhibitor of PTP1B in clinical stage development that functionally inhibits PTP1B in the periphery and in the hypothalamus. This dual mechanism of action, with the demonstrated ability to cross the blood-brain barrier, makes MSI-1436 an exciting therapeutic for further clinical study."

About Trodusquemine (MSI-1436)

Trodusquemine is a centrally and peripherally-acting appetite suppressant and the firs
'/>"/>

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
3. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
4. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
5. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
6. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
7. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
8. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
9. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
10. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
11. Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Calif. , May 23, 2013 More ... cancer may not benefit from chemotherapy and still have ... the launch of one of the largest sources of ... new website and interactive Facebook page provide recently diagnosed ... they can safely avoid chemotherapy. "We anticipate ...
(Date:5/23/2013)... Calif. , May 23, 2013 Anthem ... program that would have required them to obtain their ... by Consumer Watchdog and Whatley Kallas LLC.  ... Superior Court, alleged that Blue Cross,s mandatory mail order ... threatening their health and privacy. "This settlement ...
(Date:5/23/2013)... Texas , May 23, 2013  Texas, premier ... to deliver doctors the survival tools they need to ... compete in today,s health care marketplace. "I ... will save local practices," said Stephen L. ... Association (TMA). " Texas doctors are ...
Breaking Medicine Technology:Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3TMA Launches Physician Services Organization for Patient Care 2TMA Launches Physician Services Organization for Patient Care 3TMA Launches Physician Services Organization for Patient Care 4
... Qmed .com , the world,s only 100% ... engine, and central industry resource, today announced a ... ground-breaking detailed reports of industry-related adverse events, ... http://photos.prnewswire.com/prnh/20120423/LA91769LOGO )   (Logo: http://photos.prnewswire.com/prnh/20101214/LA16070LOGO ...
... BEACH, Fla., April 23, 2012  SurgLine International, Inc. ... International, Inc. ("SGLN") and SurgLine, Inc. ("SurgLine") stated ... SurgLine has formed SurgLine MDC Holdings, LLC. ("SMDC"), ... owned subsidiary.  SMDC will be forming  joint-venture opportunities ...
Cached Medicine Technology:Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events 2Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events 3Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events 4SurgLine International, Inc. Launches A Wholly Owned Operating Subsidiary To Pursue Cost Containment Strategies 2
(Date:5/23/2013)... May 23, 2013 Live ... contemporary services, provides the best business lead solution ... Its Call center Management solution features Free Web ... Call Limitation, Do-Not-Call Maintenance and "Automatic Transfer Retry". ... comprehensive campaign delivery and management system. , Its ...
(Date:5/23/2013)... drug about to be tested in a clinical trial ... treatment for Alzheimer,s disease has failed to work with ... patients, according to results of a study by University ... of neuroscience affiliated with the Evelyn F. and William ... emphasized the importance of verifying promising research results before ...
(Date:5/23/2013)... poor prognosis, with limited treatment options. In some ... it,s supposed to. New research from Western University explains ... identifies a mechanism to rectify that. ... team at Western,s Schulich School of Medicine & Dentistry, ... the death of cancer cells by binding to and ...
(Date:5/23/2013)... New York, New York (PRWEB) May 23, 2013 ... products manufactured by C.R. Bard, Inc., continue to move ... District Court, Southern District of West Virginia, Bernstein Liebhard ... 17th, the Court denied a request by C.R. Bard ... claimed would reveal trade secrets and other confidential, proprietary ...
(Date:5/23/2013)... 2013 Former United States Vice President ... Acadian 's annual Paramedic Luncheon. , In front ... Cheney praised Acadian's medics, saying, "I am delighted to ... awarding the Paramedic of the Year Award. I think ... lot of competition within a company like this because ...
Breaking Medicine News(10 mins):Health News:Live Lead Pros Announces The Benefits of Comprehensive Campaign Delivery and Management System 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 3Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 2Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 3Health News:Acadian Ambulance Honors Paramedic of the Year at Annual Luncheon 2
... which is ill-equipped to cope, say experts. The amount of ... and rising, suggests health data. ,India has a population of ... developing diabetes later in life, and are certainly more vulnerable ... coronary heart disease. ,Part of the blame falls ...
... is bad for health. ,It seems that smokers have a ... heart disease in their blood. The discovery could help explain ... attacks than non-smokers. ,Paraoxonase is a enzyme which ... blood vessels. A team of Swiss researchers examined 367 people ...
... weapons go, anthrax is nowhere as terrifying as several others, ... University. Smallpox would be a lot worse. The government now ... Experiments are getting underway to see whether it can be ... still be effective. // ,“Anthrax is not ...
... less than 1mm in diameter, presents a new opportunity for ... Hollywood film technicians who worked alongside Dr Nicolas Beechey-Newham and ... at Guy’s Hospital in London to produce the “micro-camera”. ... the opening in a nipple – is able to view ...
... efficacy of a malaria drug are being questioned by ... be withdrawn. Manufacturer GlaxoSmithKline markets the anti-malarial drug Malarone ... at preventing the aggressive falciparum strain of malaria, but ... the Consumers’ Association – says the evidence for this ...
... be more likely to create illness than the weapons themselves, ... result of panic caused by the news of anthrax attacks. ... the UK, US and Australia predicted that while bioweapons themselves ... is having a devastating effect. ,Already, there are ...
Cached Medicine News:Health News:Diabetes on the rise, 2Health News:All the more bad, 2